Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

Phase 2

Completed

• Conditions: Colorectal Neoplasms

• Registration Number: NCT00361842
• Lead Sponsor: Jazz Pharmaceuticals

Brief Summary

The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan. All patients will receive CPX-1 at a dose of 210 units/m2 over 90 minutes every two weeks.

Detailed Description

CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine. The two drugs are present inside the liposome in a fixed 1:1 molar ratio. CPX-1 was developed as a means of delivering and preserving a fixed 1:1 molar ratio of the two drugs. This ratio was found in vitro and in vivo models of cancer to have synergistic anti-cancer activity and preservation and delivery of this ratio is important because other ratios of these two drugs have been found to be antagonistic or only additive. Both floxuridine and irinotecan HCl are active chemotherapeutic agents, each approved for clinical use in the United States and Canada for colorectal cancer. Current practice routinely administers 5- fluorouracil with irinotecan in combination regimens in first or second line treatment without the means of preserving the synergistic ratio.

Study Timeline

• Study Start: 2006-07
• Study First Submitted: 2006-08-07
• Study First Submitted QC: 2006-08-07
• Study First Posted: 2006-08-09
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Disposition First Submitted: 2012-05-16
• Disposition First Submitted QC: 2012-05-16
• Disposition First Posted: 2012-05-18
• Results First Submitted: 2021-04-28
• Status Verified: 2021-07
• Results First Submitted QC: 2021-07-01
• Last Update Submitted: 2021-07-01
• Results First Posted: 2021-07-02
• Last Update Posted: 2021-07-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

• Ability to understand and voluntarily sign an informed consent form

• Age > 18 years at the time of signing the informed consent form

• Histological confirmation of advanced stage, primary or metastatic colorectal carcinoma

• Prior therapy (Group 1, irinotecan naive):

  • No more than one regimen for metastatic disease
  • No more than two regimens overall; one for neoadjuvant/adjuvant and one for metastatic/advanced disease

• Prior therapy (Group 2, irinotecan refractory):

  • Disease progression on or within 3 months after prior irinotecan-containing regimen
  • CPX-1 treatment must start within 6 months after documentation of disease progression on irinotecan (other therapies are permitted after irinotecan and before study entry)

• Must have measurable disease as defined by RECIST

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

• Able to adhere to the study visit schedule and other protocol requirements

• Life expectancy of at least 24 weeks

• Laboratory values fulfilling the following:

  • Absolute neutrophil count (ANC) >1500 cells/mm3 (1.5 x 109/L)
  • Platelet count > 100,000/mm3 (100 x 109/L)
  • Serum creatinine <1.5 x upper limits of normal (ULN)
  • Serum SGOT/AST and SGPT/ALT <3 x upper limits of normal (ULN) (<5 times ULN if caused by liver metastases)
  • Serum total bilirubin < 1.25 x upper limits of normal (<2 times ULN if caused by liver metastases)

• All men and women must agree to practice effective contraception during the study period and for three months afterward if not otherwise documented to be infertile.

• Prior radiation therapy must be completed at least 4 weeks prior to enrollment and the patient recovered from any toxicity related to the radiation therapy.

Exclusion Criteria

• Prior treatment with irinotecan or an irinotecan-containing regimen (Group 1 only)
• Intolerant of an irinotecan-containing regimen (Group 2 only)
• Without documented evidence of irinotecan-refractoriness (Group 2 only)
• Chemotherapy or investigational anticancer therapeutic drugs in the four weeks prior to study entry.
• Hypersensitivity to irinotecan, floxuridine or liposomal products.
• History of Wilson's disease or other copper-related disorder.
• Clinically significant cardiac disease (New York Heart Association Class III or IV).
• Severe debilitating pulmonary disease.
• Active infection requiring continuing intravenous antibiotic treatment; recent infections must have resolved at least 5 days
• Severe or active enteropathy or recurrent onset of diarrhea, defined as an excess of 2 to 3 stools above the normal daily rate within the past four weeks.
• Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form.
• Pregnant or lactating women. Continued use of a drug or other product known to induce or inhibit CYP3A4. ---Patients must discontinue these products for at least 2 week prior to enrollment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Progression-free Survival (PFS) Per RECIST Version 1.0	Every 8 weeks	Progression-free survival (PFS) was defined as the time from the first dose to the documentation of progressive disease (PD), death, or lost to follow-up at last assessment visit.
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0	From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months	Disease response was assessed using RECIST 1.0. Measurable disease and target lesions were determined prior to study entry. Changes in the largest diameter (unidimensional measurement) of the sum of the target tumor lesions were used in the RECIST criteria. Best response on study was classified as follows. Complete Response (CR), disappearance of all clinical and radiological evidence of tumor. Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of the longest diameters. Stable Disease (SD), steady state of disease. Neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD. Progressive Disease (PD) at least a 20% increase in the sum of the longest diameters of measured lesions taking as references the smallest sum of longest diameters recorded since the treatment started. Appearance of new lesions also constituted progressive disease.

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DoR) Per RECIST Version 1.0	Every 8 weeks	The duration of overall response was measured from the time that measurement criteria were met for CR or PR (whichever status was recorded first) until the first date that recurrent or progressive disease was objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The duration of overall complete response was measured from the time measurement criteria were first met for complete response until the first date that recurrent disease was objectively documented.

Trial Locations

Locations (12)

California Cancer Center; 🇺🇸 Greenbrae, California, United States

Lombardi Comprehensive Cancer Research Institute, Georgetown University Medical Center; 🇺🇸 Washington, District of Columbia, United States

Broward Oncology Associates; 🇺🇸 Fort Lauderdale, Florida, United States

NW Oncology & Hematology Associates; 🇺🇸 Coral Springs, Florida, United States

St. Joseph's/Candler Health System Inc.; 🇺🇸 Savannah, Georgia, United States

Sir Mortimer B. Davis Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada

Sarah Cannon Research Institute; 🇺🇸 Nashville, Tennessee, United States

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada

Cancer Care Oklahoma; 🇺🇸 Tulsa, Oklahoma, United States

Gabrail Cancer Center; 🇺🇸 Canton, Ohio, United States

South Carolina Oncology Association; 🇺🇸 Columbia, South Carolina, United States

Presbyterian Hospital; 🇺🇸 Charlotte, North Carolina, United States